Axonics announced that the Patent Trial and Appeal Board – PTAB – of the USPTO has issued written decisions on two Medtronic patents that Axonics is contesting. Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics’ proprietary tined lead design. Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic’s ‘314 patent and declined to invalidate the challenged claims in the ‘756 patent over one Administrative Patent Judge’s dissenting opinion. The district court case where Medtronic has asserted these patents is currently stayed based on these IPRs as well as pending IPRs on other Medtronic asserted patents. Axonics plans to seek review of the PTAB’s finding that the remaining claims were not unpatentable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
